Experts in the treatment of Parkinson’s Disease are hopeful that the FDA will grant approval for a transdermal rotigotine patch that will be marketed under the name Neupro. The patch is already being sold and used in Europe.

The patch provides for a continuous, steady delivery of a drug shown to be effective in 48% of all Parkinson’s patients.

The results of a six-month study of the effectiveness of the patch will be published in the January 23 issue of the journal Neurology.

Parkinson’s Patch Nears U.S. Approval - WebMD